Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease (VINCA-CKD)

• Change in markers of inflammation including Interleukin (IL)-1, IL-6 TNF-alpha, MMP-9 and serum amyloid A [ Time Frame: 1 year ] [ Designated as safety issue: No ]
• Effect on known Coronary Artery Disease risk factors including lipids and blood pressure. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
• Effect on Carotid Intima-media thickening (CIMT) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
• Assess safety in high risk patients with Coronary Artery Disease and Chronic Kidney Disease [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

• Change in markers of inflammation including IL-1, IL-6 TNF-alpha, MMP-9 and serum amyloid A [ Time Frame: 1 year ] [ Designated as safety issue: No ]
• Effect on known Coronary Artery Disease risk factors including lipids and blood pressure. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
• Effect on Carotid Intima-media thickening (CIMT) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
• Assess safety in high risk patients with Coronary Artery Disease and Chronic Kidney Disease [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

The purpose of this study is to determine if vitamin D supplementation changes the results of certain tests associated with inflammation in the body using an oral, synthetic form of vitamin D called paricalcitol.

Vitamin D deficiency is common and has been associated with an increased risk of heart disease. In patients with the combination of kidney disease and heart disease, inflammation is thought to contribute to a high rate of cardiac events. Less is known about the effects of vitamin D supplementation on certain tests associated with inflammation in the body.

• Coronary Artery Disease
• Chronic Kidney Disease
• Hypovitaminosis D
• Secondary Hyperparathyroidism

• Drug: paricalcitol
  2 mcg oral paricalcitol daily
  Other Name: Zemplar
• Drug: placebo
  placebo

• Experimental: oral paricalcitol 2 mcg daily
  oral paricalcitol 2 mcg daily
  Intervention: Drug: paricalcitol
• Placebo Comparator: Placebo
  one oral placebo drug daily
  Intervention: Drug: placebo

Inclusion Criteria:

• Men and non-pregnant, non-lactating women greater than 18 years of age
• Able to given informed consent and complete scheduled visits
• History of established coronary artery disease as defined by coronary stenosis in one or more vessels greater than or equal to 70% by coronary angiography or CT angiogram OR abnormal stress test (at least medium-sized, moderate reversible defect) OR a presence of a CAD risk equivalent as defined by the NCEP ATP III as: Framingham risk score ≥ 20%, diabetes, or peripheral arterial disease(4)
• hs-CRP ≥ 2.0 mg/L
• History of stage 3 or 4 CKD defined as an eGRF by the MDRD equation of 15-60 mL/min/1.73 m2
• Low level of serum 25-hydroxyvitamin D (<30ng/mL)
• Evidence of secondary hyperparathyroidism defined as intact parathyroid hormone (iPTH) level > 70 pg/mL
• Stable dose of statin and/or other lipid lowering therapy (ie: ezetimibe, fibrates, bile acid sequestrants nicotinic acid, fish oil) for 12 weeks prior to enrollment without known plans for change to current therapy during the study period

Exclusion Criteria:

• History of myocardial infarction, stroke, or cardiac surgery within 6 months of enrollment
• History of carotid artery surgery
• Planned cardiovascular surgery or procedure, with the exception of permanent pacemaker placement, in the next 18 months.
• Use of vitamin D or calcium supplementation within the past 12 weeks with the exception of calcium containing phosphate binders and a daily multivitamin containing ≤ 400 IU of vitamin D
• Hypercalcemia (as defined by the laboratory upper limit of normal ) or hyperphosphatemia (≥ 5.5 mg/dL)
• Plan to initiate renal replacement therapy (dialysis) during the study
• History of left ventricular systolic dysfunction with an ejection fraction <50% or history of New York Heart Association functional Class II-IV congestive heart failure
• Uncontrolled blood pressure, defined as systolic blood pressure greater than 160 mmHg and diastolic blood pressure greater than 100 mm Hg at the screening visit
• Uncontrolled diabetes, defined as hemoglobin A1C ≥ 10.0
• History of any surgery within the past 3 months or known to be planned during the study period
• History of malignancy within the past 5 years with the exception of non-melanoma (ie: squamous cell or basal cell) skin cancer
• History of a known systemic or pulmonary inflammatory condition (including rheumatoid arthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease, pulmonary fibrosis, sarcoidosis, Wegener's granulomatosis, Goodpasture's disease)
• History of renal or other organ transplant and/or immunosuppressed state (ie immunosuppressive therapy or condition such as HIV)
• History of any other condition, that in the opinion of the investigators renders it unsafe for the subject to be enrolled
• For woman able to become pregnant, unwillingness to use birth control
• Participation in another clinical trial